NCT03563638

Maternal Serum Pentraxin 3 in Early Pregnancy to Predict Gestational Diabetes Mellitus

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 824 (actual)
• Sponsor: Shanghai First Maternity and Infant Hospital · Academic / Other
• Sex: Female
• Age: 27 Years – 33 Years
• Healthy volunteers: Accepted

Summary

To investigate the association of maternal serum concentrations of pentraxin 3 in early pregnancy with gestational diabetes mellitus and to explore its potential value in the prediction of GDM.

Detailed description

We recruited all pregnant women for the first checkup in our hospital . Maternal fasting serum PTX3 levels, fasting plasma glucose and fasting insulin and other factors were measured. Oral glucose tolerance test (OGTT) was performed at 24-28 weeks in all participants. According to the occurrence of GDM, subjects were divided into two groups: GDM group and normal glucose tolerance (NGT) group.

Conditions

• Pregnancy Complications Affecting Fetus (Diagnosis)

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	75gOGTT	oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.

Timeline

• Start date: 2015-10-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2018-06-20
• Last updated: 2018-06-20